Document Detail

Restoring patency of occluded central venous catheters.
MedLine Citation:
PMID:  7356837     Owner:  NLM     Status:  MEDLINE    
Thrombotic occlusion remains a major cause of central venous catheter removal prior to completion of therapy. Injection of a dilute solution of a potent fibrinolytic agent, urokinase or streptokinase, into the occluded Silastic central venous catheter consistently reestablishes its patency. This procedure was performed on 352 occluded silicone elastomer central venous catheters with only one failure and one minor complication. We recommend this technique for restoring patency of occluded silicone elastomer central venous catheters.
M R Hurtubise; J C Bottino; M Lawson; K B McCredie
Related Documents :
25175947 - Use of the nellix evas system to treat post-evar complications and to treat challenging...
12848317 - Central venous catheter occlusion and thrombosis.
16363317 - A novel method of measuring cardiac output in infants following extracorporeal procedur...
9437697 - Central venous catheter access.
10721257 - Transvenous embolization of carotid-cavernous sinus fistula associated with a primitive...
15232377 - Patterns of collateral pathways in extrahepatic portal hypertension as demonstrated by ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of surgery (Chicago, Ill. : 1960)     Volume:  115     ISSN:  0004-0010     ISO Abbreviation:  Arch Surg     Publication Date:  1980 Feb 
Date Detail:
Created Date:  1980-03-27     Completed Date:  1980-03-27     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9716528     Medline TA:  Arch Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  212-3     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Catheters, Indwelling / adverse effects*
Fibrinolytic Agents / therapeutic use*
Silicone Elastomers
Streptodornase and Streptokinase / therapeutic use
Thrombosis / drug therapy*,  etiology
Urokinase-Type Plasminogen Activator / therapeutic use
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Silicone Elastomers; EC 3.-/Streptodornase and Streptokinase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chronic granulomatous disease in an adult with recurrent abscesses.
Next Document:  Protecting the high-risk rectal anastomosis.